Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Pierce

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus ErythematosusEllen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, et al.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
The Lancet. Rheumatology|January 27, 2024
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialSaira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus ErythematosusEllen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, et al.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
The Lancet. Rheumatology|January 27, 2024
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialSaira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, et al.
Pageof 3